Monitor the FY27 Q2 earnings release for actual revenue and adjusted EBITDA figures to validate the sequential growth guidance. The accretive Safari Flower acquisition and UK expansion provide potential upside catalysts, but execution risk remains. The strong balance sheet ($149M cash, no debt) limits downside risk.
Price Chart
Executive Summary
Aurora Cannabis issued a business update reaffirming FY27 Q2 guidance for sequential growth in net revenue and adjusted EBITDA, highlighting the accretive acquisition of Safari Flower Company (EU-GMP certified), strong performance in Germany and Poland (#1 market share by revenue in Poland), and UK expansion via recent acquisitions. The company reported $149M cash and no debt as of June 30, 2026. The filing is forward-looking with no hard financial results reported, making it a neutral-to-modestly-positive operational update rather than a material catalyst.
Key Facts
- Reaffirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA.
- Safari Flower Company received EU-GMP certification in July and is expected to contribute incremental net revenue and adjusted EBITDA.
- Aurora holds #1 market share by revenue in Poland and reports strong performance in Germany.
- UK market expansion underway with recently announced acquisitions of Internode Pharma and HAP Pharma Limited.
- Cash position of $149 million as of June 30, 2026, with no debt.
- ATM program will only be used when the Board determines it is in the best interest of the Company.
- Estimated $9 billion global medical cannabis market cited as opportunity.
Financial Impact
No specific financial figures reported; guidance for sequential growth in net revenue and adjusted EBITDA reaffirmed. Cash balance of $149M as of June 30, 2026.
Risk Factors
- Forward-looking guidance may not materialize; sequential growth is not guaranteed.
- Integration risks from multiple acquisitions (Safari Flower, Internode Pharma, HAP Pharma).
- Regulatory changes in global medical cannabis markets could impact growth trajectory.
- ATM program usage could dilute shareholders if activated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000887 |
| Document: aurora_6k.htm | 0001279569-26-000887 |
| Document: 0001279569-26-000887-index-headers.html | 0001279569-26-000887 |
| Document: 0001279569-26-000887-index.html | 0001279569-26-000887 |
| Document: 0001279569-26-000887.txt | 0001279569-26-000887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.87 | awaiting T+5 | — | $3.90 (+0.78%) |
Oct 14, 2026 12d ago | 6-K | $4.10 $3.97 | ▼ −3.17% | ▼ −2.16% | $3.90 (−4.88%) |
Oct 8, 2026 18d ago | 6-K | $4.43 $4.10 | ▼ −7.45% | ▼ −7.17% | $3.90 (−11.96%) |
Oct 6, 2026 20d ago | 6-K | $4.46 $4.17 | ▼ −6.50% | ▼ −5.52% | $3.90 (−12.56%) |
Oct 5, 2026 21d ago | 6-K | $4.59 $4.29 | ▼ −6.54% | ▼ −6.40% | $3.90 (−15.03%) |
Sep 16, 2026 5w ago | 6-K | $3.83 $4.22 | ▲ +10.18% | ▲ +7.62% | $3.90 (+1.83%) |
Sep 14, 2026 6w ago | 6-K | $3.81 $4.03 | ▲ +5.77% | ▲ +5.67% | $3.90 (+2.36%) |
Sep 9, 2026 6w ago | 6-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.63% | $3.90 (+0.52%) |
Sep 2, 2026 7w ago | 6-K | $4.03 $3.73 | ▼ −7.44% | ▼ −6.49% | $3.90 (−3.23%) |
Aug 24, 2026 9w ago | 6-K | $3.94 $4.05 | ▲ +2.79% | ▲ +2.32% | $3.90 (−1.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers